Cargando…

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone

Background: The effects of mineralocorticoid receptor antagonists, including the newly introduced esaxerenone, on renal function remain uncertain. Methods and Results: This retrospective study was performed on patients who received esaxerenone for resistant hypertension between November 2019 and Jun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oshima, Akira, Imamura, Teruhiko, Narang, Nikhil, Kinugawa, Koichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Circulation Society 2021
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180375/ https://www.ncbi.nlm.nih.gov/pubmed/34136708 http://dx.doi.org/10.1253/circrep.CR-21-0024

Ejemplares similares

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with Heart Failure and Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Negative Prognostic Impact of Mineralocorticoid Receptor Antagonist in Elderly Patients Receiving TAVR
por: Imamura, Teruhiko, et al.
Publicado: (2023)

Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate
por: Oshima, Akira, et al.
Publicado: (2021)

Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats
por: Rahman, Asadur, et al.
Publicado: (2021)

Mineralocorticoid receptor blockade for renoprotection
por: Cha, Dae Ryong
Publicado: (2018)

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone
por: Rakugi, Hiromi, et al.
Publicado: (2020)

Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Risk Factors for Rapid Recurrence of Hyperkalemia following Cessation of Sodium Zirconium Cyclosilicate
por: Imamura, Teruhiko, et al.
Publicado: (2022)

SUN-176 A Case of Aldosterone-Producing Adenoma with Preoperative Use of a Novel Mineralocorticoid Receptor Antagonist Esaxerenone
por: Yamanami, Hiroaki
Publicado: (2020)

Adaptive Servo-Ventilation as a Novel Therapeutic Strategy for Chronic Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Implications of Doppler Echocardiography-guided Heart Rate Modulation Using Ivabradine
por: Hori, Masakazu, et al.
Publicado: (2021)

Pressure Ramp Testing for Optimization of End-Expiratory Pressure Settings in Adaptive Servo-Ventilation Therapy
por: Hori, Masakazu, et al.
Publicado: (2021)

Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure
por: Nakagaito, Masaki, et al.
Publicado: (2021)

Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Patient Selection for Pemafibrate Therapy to Prevent Adverse Cardiovascular Events
por: Izumida, Toshihide, et al.
Publicado: (2022)

Chronotype of Lung Fluid Levels in Patients with Chronic Heart Failure
por: Ueno, Yohei, et al.
Publicado: (2022)

Lung Fluid Volume during Cardiopulmonary Exercise Testing
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study
por: Kario, Kazuomi, et al.
Publicado: (2020)

Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker
por: Chang, Wei-Ting, et al.
Publicado: (2021)

Prognostic Implication of Small Dense LDL-Cholesterol Levels following Acute Coronary Syndrome
por: Imamura, Teruhiko, et al.
Publicado: (2023)

Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2016)

A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice
por: Munkhjargal, Uugantsetseg, et al.
Publicado: (2023)

Change in Lung Fluid Volume during Exercise in Patients with Exercise-Induced Mitral Regurgitation
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Practical Therapeutic Management of Percutaneous Atrial Septal Defect Closure
por: Tanaka, Shuhei, et al.
Publicado: (2021)

Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone
por: Qiang, Panpan, et al.
Publicado: (2022)

The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial
por: Okuda, Yasuyuki, et al.
Publicado: (2022)

Novel Ramp Test to Optimize Pressure Setting of Adaptive Servo-Ventilation Using Non-Invasive Lung Fluid Level Quantification
por: Hori, Masakazu, et al.
Publicado: (2022)

Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism
por: Satoh, Fumitoshi, et al.
Publicado: (2020)

Inadequate Cardiac Unloading Following Transcatheter Aortic Valve Replacement
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Prognostic Impact of Polypharmacy following Trans-Catheter Aortic Valve Replacement
por: Imamura, Teruhiko, et al.
Publicado: (2023)

Prognostic Impact of Baseline Six-Minute Walk Distance following Trans-Catheter Aortic Valve Replacement
por: Imamura, Teruhiko, et al.
Publicado: (2023)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Effect of add-on sacubitril/valsartan on the left ventricular hypertrophy of a patient with hypertension
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
por: Sun, Li‐Jing, et al.
Publicado: (2017)

Successful Management of Pheochromocytoma Crisis with Cardiogenic Shock by Percutaneous Left Ventricular Assist Device
por: Nakamura, Makiko, et al.
Publicado: (2022)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b0smcet2uban3ro2tsvn1s0vvp